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Abstract
The SARS-CoV-2 virus has spread rapidly, resulting in a global pandemic.There is a great need for an effective drug cocktail therapy to combat Acute Respiratory Distress Syndrome (ARDS), a major cause of death due to COVID-19.The two drugs examined
are metformin, an antidiabetic medication, and rapamycin. Rapamycin is often prescribed for transplant patients as it has an
immunosuppressive effect. The aim of the investigation was to determine the efficacy of metformin and rapamycin in treating
COVID-19, and to examine what an effective protocol would look like. These two drugs both inhibit mTOR and can reduce the
body’s auto-immune response, which destroys bronchial cells via cytokine storms. Both drugs have a long history of clinical use and
have sufficient evidence of efficacy. They possess antiviral properties and downregulate inflammatory markers, making them excellent candidates for further study, both individually and in combination. Rapamycin has been shown to reverse markers of aging
and can help repair organ damage. Importantly, metformin can help negate the toxic side effects of the potent rapamycin, while
still preserving the positive effects of the compound. Metformin also has been shown to aid those who are at risk of developing
ARDS due to comorbidities such as diabetes or hypertension. As such, using metformin as a preventative therapy, either alone or
with small doses of rapamycin, may be warranted in patients at risk (Hussain et al, 2020) (Malhotra et al, 2020).
Introduction
The SARS-CoV-2 virus’s lethality can be largely owed to
Acute Respiratory Distress Syndrome (ARDS), a major
cause of death due to COVID-19. The lungs become inflamed and are heavily damaged as fluid from the blood
vessels leaks into the lungs, obstructing breathing and depriving the organs of adequate amounts of oxygen. This
results in high morbidity and mortality rates. The overall
percentage of mortality in patients with ARDS was 40
percent, making the disorder of primary importance in
the search to reduce deaths in the patient population
(Tzotzos et al., 2020).
The ability to repurpose drugs is vitally important to
combat novel pathogens and can shorten the amount of
time and money required to develop an effective protocol. Novel viruses often use elements of central pathways
that are commonly used by other viruses.Therefore, drugs
that have been previously developed can prove efficacious,
as they target the same pathway. Additionally, the drugs
that are currently in use have already been proven to be
effective and safe, which allows their immediate use until
another, more pathogen-specific, drug can be developed.
Furthermore, modeling the drug after an existing therapeutic agent can shorten the amount of time and energy
required to develop a new agent, as portions of the previous drug can be used as a starting point.This can all add to
an advantage that may save countless patients’ lives as they
wait for a new drug to be developed (Husain et al, 2020).
One of the more interesting drugs proposed as a therapeutic involves the use of metformin, an anti-diabetic medication.This drug has been touted for its anti-inflammatory
effects and seems to have a positive effect on the mortality
rate of patients suffering from COVID-19, even though the
exact mechanism of action remains contested. Possible
theories range from its ability to act as a strong base, disrupting the viral envelope, to its ability to up-regulate the
ACE-2 enzyme, the critical binding site for the spike protein that serves as the virus’ entry point (Scheen, 2020).

Another potential drug being offered as therapy is rapamycin. Rapamycin first gained recognition as an anti-rejection medication for transplanted organs. It suppresses
the immune system, resulting in less inflammation, and
has a protective effect, shielding the patient from ARDS.
Rapamycin can ensure that even if a cure for the virus
remains elusive, we can mitigate the negative physiological
effects of the illness on the patients. It would therefore be
advantageous to examine the differing protocols involving metformin and rapamycin for their efficacy in treating
COVID-19 generally, and ARDS specifically, in vulnerable
patient populations (Husain et al, 2020).
Methods
Several databases (PubMed, Medscape, clinicaltrials.gov)
were systematically reviewed for the relevant literature.
Papers concerning the effects of metformin and rapamycin were studied extensively, both in relation to COVID19 as well as other illnesses.
Discussion
Metformin is a drug that is generally used in the treatment
of type 2 diabetes as well as other metabolic conditions.
Its widespread use and its minor side effects have led to
it being christened the “aspirin of the 21st century.” It
was originally introduced as an anti-influenza medication
before being used for its effects on glucose reduction. It
works primarily by decreasing the production of hepatic glucose while simultaneously increasing the action of
insulin on tissues, combatting a major factor of type 2
diabetes. Metformin did not achieve widespread use in
the United States until 1995, yet by the year 2017, it was
the fourth most prescribed medication in the United
States. Even though the exact mechanisms of metformin
are unknown, there are multiple proposed mechanisms
of action, including inhibition of the respiratory chain in
complex I of the mitochondria and lowered production
of cyclic AMP. Cyclic AMP is the major activating factor for
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protein kinase A, an essential part of the second messenger pathway involved in hormonal regulation. This greatly
assists the uptake of glucose, preventing insulin resistance,
the primary cause of type 2 diabetes. Insulin resistance is
caused by an overproduction of insulin, which causes the
bodily tissues to require more of the molecule to uptake
glucose, resulting in the increasing inability of glucose to
migrate into the resistive tissue (Sharma et al, 2020).
The SARS-CoV-2 virus initially binds to the angiotensin-converting enzyme 2 (ACE2). The virus uses its spike
protein (S) region to bind to the enzyme, forming a complex that allows the virus entry into the cell. After gaining
entry to the host, the virus will downregulate the ACE2
receptor, leading to excessive inflammation, including cardiovascular damage and ARDS.The inflammation is due to
ACE2/Ang (1-7)/Mas acting within the Renin Angiotensin
Aldosterone System (RAAS) as the anti-inflammatory
element to counteract the ACE1–Ang II pro-inflammatory arm. The inflammatory arm causes elevated systemic
blood hypertension and inflammation. Metformin is hypothesized to be able to counteract the downregulation
of the ACE2 receptor through stimulation of the AMPK/
mTOR pathway. The AMPK/mTOR pathway is thought to
be involved in increasing the upregulation and stability of
ACE2, by phosphorylating ACE2 Ser680. (Malhotra et al,
2020). Although clinical evidence in vivo is required, there
is strong evidence that Metformin upregulates ACE2,
from studies with human umbilical vein endothelial cells
(HUVECs) and human embryonic kidney 293 (HEK293T)
cells (Zhang et. al. 2018b). Additionally, phosphorylation decreases ubiquitination, extending its half-life.
Furthermore, the phosphorylation of the ACE2 enzyme
by a large negative phosphate group would change its 3D
conformation and sterically hinder the binding complex
that the virus uses for entry. In this way, metformin can
decrease the ability of the virus to enter the host and
reduce mortality through its upregulation of the ACE-2
receptor (Malhotra et al, 2020).
There is evidence that by upregulating ACE-2,
Metformin can exhibit a protective effect on the cardiopulmonary system through the AMPK pathway. AMPK
activation often leads to ACE2 conformational changes
leading to SARS-CoV-2 having a greater difficulty binding
to the receptor (Malhotra et. al. 2020). A study found that
in animal models “Transgenic mice overexpressing the
phosphomimetic ACE2 S680D exhibit less damage in pulmonary vasculature under injurious conditions” (Zhang
et al., 2018). Metformin has also been shown to have a
healing effect on the pulmonary system in lipopolysaccharides in animal models (Jian et al., 2013).
The glucose-lowering effects of metformin seem to
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have a significant effect on survivability. Hyperglycemia
has been labeled a major risk factor in various Chinese
studies studying pulmonary illnesses. (Chen et al, 2015). A
study of patients with diabetes and COVID-19 found that
patients with well-controlled blood glucose levels had a
much better prognosis and overall reductions in mortality
(Crouse et al, 2020). As such, metformin’s proven ability to
aid in the treatment of type 2 diabetes is important for diabetic patients that contract COVID-19. Another study has
demonstrated that there is a direct correlation between
the SARS-CoV-2 virus and diabetes, leading to speculation
that the virus can enter the cells of the pancreatic islets
where there is an expression of the ACE2 enzyme. This
leads to damage to the pancreatic beta cells, which produce
insulin, leading to transient type 2 diabetes mellitus (Yang,
2010). This would indicate that the regulation of diabetes
is of primary importance for the treatment of COVID-19.
Metformin’s previously stated effects on insulin sensitivity
would make it an ideal candidate.
Two retrospective studies of COVID-19 patients with
diabetes from China in early 2020 found that Metformin
could provide benefit. In a study of diabetic patients, the
mortality rate for patients on metformin was lower than
the group that did not receive the drug. This was despite
the metformin patients having higher levels of fasting glucose on admission. The length of the hospital stay was
the same between the two groups. (Luo et al. 2020). The
SARS-CoV-2 and Diabetes Outcome study in France initially showed that patients who were given metformin
before admissions had a lower mortality rate after seven
days (Cariou et al, 2020). However, multiple confounding
factors needed to be accounted for, which once considered, rendered the findings no longer significant.
In a retrospective analysis studying whether Metformin
had any favorable effects 1,213 type 2 diabetic patients
with COVID-19 in 16 hospitals in Hubei, China were
examined. They excluded confounding variables such as
eliminating patients with a glomerular filtration rate of
less than 30ml/min or who had cirrhosis. Patients exclusively using insulin were also eliminated. They looked
at patients treated with metformin and other drugs
compared to just other diabetic medications. They used
propensity score matching to adjust for confounding
variables and used a Cox regression model to account
for the changes in clinical conditions throughout the patients’ stay. They discovered that the length of stay and
the 28 days all-cause mortality rate were both unchanged,
though metformin was associated with higher levels of
acidosis (Lui et al, 2020). Metformin had a protective
effect, guarding against heart failure and the body’s various inflammatory responses. Markers of heart failure,
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inflammation, and cardiac injury were examined, and all
were found to be lower. With these data taken together,
according to the results of the study, Metformin exhibits a
positive effect on cardiac failure and inflammation (Cheng
et al., 2020). This was particularly true in severe cases but
did not translate into an overall reduction in mortality.
The studies’ discovery that Metformin does not influence
mortality was contrasted by alternate findings in which
researchers had found an improvement in patients using
Metformin (Luo et al.2020). It is possible that since in
the Luo study, patients on insulin were included in the
non-Metformin group, there was a confounding variable
that biased the results.
The poor outcomes of diabetic patients can be explained by several factors. Patients with diabetes generally live with greater levels of overall inflammation daily,
putting their already inflamed tissues at an increased
risk of destruction of the bronchial epithelium by the
body’s immune system, resulting in ARDS (Azar et al,
2020). Elevated levels of glucose in patients with diabetes is an additional risk factor as high blood glucose
levels have been shown to depress the immune system
(Ceriello et al, 2020). These reasons make metformin a
viable candidate for the treatment of diabetes in COVID19 patients, particularly as its glucose-lowering effects
can help mitigate the negative role of diabetes (Kow et
al, 2021). Additionally, there seem to be positive effects
independent of the reduction of blood glucose. Various
biochemical mechanisms are involved in Metformin’s suppression of inflammatory cytokines, which would aid in
the prevention of an overwhelming immune response on
the part of the host (Lui et al, 2020).
Metformin’s can play a role in the reduction of inflammation in patients either with or at a high risk of contracting ARDS (Acute Respiratory Distress Syndrome).
Metformin has proven to be effective at diminishing
cytokine storms, an immune response that damages the
body’s cells. It does this by inhibiting interleukin 1α and
1β, important kinases for pro-inflammatory action. The
standard measure of systemic inflammation is the neutrophil to lymphocyte ratio, which is used as a marker.
Tracking these markers showed an overall reduction of
inflammatory cytokines. In a follow-up study of nondiabetic patients with heart failure, it was demonstrated
that metformin suppressed plasma cytokines (Cameron
et al, 2016). This makes metformin a viable choice in the
prevention of inflammation and the formation of ARDS.
The pathway that metformin uses in its anti-inflammatory effects is by the inhibition of tumor necrosis factor-α–dependent IκB (IkappaB kinase) degradation. In
an experiment, researchers treated mouse hepatocytes

with metformin. They found that “Metformin treatment
for 3 hours suppressed TNFα-induced degradation of
the NF-κB negative regulator IκB while modulating
AMPK and mammalian target of Rapamycin signaling
in a dose-dependent manner” (Cameron et al, 2016).
Metformin also inhibited signaling downstream by inhibiting the cytokines that are normally produced and activated, 5’ AMP-activated protein kinase (AMPK). AMPK
is an enzyme that increases glucose uptake and is often
thought of as a negative regulator of inflammation. In the
same vein, IL-1β (interleukin-1-β), and IL-6 (interleukin-6)
which are both markers of TNF-α–dependent inhibition,
were greatly reduced (Cameron et al, 2016).
A 30-day study examining the mortality of nursing
home patients found that metformin was associated with
significantly less mortality (Lally et al, 2020). Additionally,
a retrospective analysis was made of claims made by the
United Health group’s Clinical Discovery database. This
study analyzed the records of enrollment of COVID19 patients across all 50 states, as well as the various
pharmacy claims and laboratory reports. They found that
when metformin was given to adults with type 2 diabetes mellitus or obesity there was a marked decrease in
mortality exclusively for women, with men receiving no
benefit.This finding partially confirms the proposed theory that metformin would be beneficial based on its known
effects of decreasing levels of tumor-necrosis-factor α
(TNFα).TNFα is of particular importance as patients with
COVID-19 have shown to have remarkably high levels of
it in their lung tissue. Patients with diabetes also have high
levels of TNFα, as diabetes has been shown to further elevate levels. Metformin also promotes the upregulation of
anti-inflammatory cytokine, IL-10. Additionally, The study
found that TNFα inhibitors were associated with reduced
mortality (Bramante et al, 2020).
This study, while interesting, has several noticeable
flaws, including the obese and overweight patient samples
and the lack of strength associated with retrospective
analysis. Additionally, patients may have been prescribed
Metformin previously, due to its prevalence, which may
have gone unreported. It is important to stress that although a helpful effect was observed, these were individuals with other comorbidities such as T2DM and obesity.
The protective effect may be much less pronounced with
a patient group that has a lower risk factor and absence
of these comorbidities.
Another factor in analyzing the results of the study is
the difference in the sensitivity required to activate mast
cells between males and females. Mast cells are an early
indicator for the SARS-CoV2 immune response. Females
exhibit a far greater increase in TNFα than their male
45
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counterparts. Metformin would therefore exhibit a greater positive effect in females, as they are naturally predisposed to a more severe reaction that can be inhibited
by the drug. Women and men differed in their cytokine
responses even though the levels of the ACE2 receptor
were equal (Bramante et al, 2020).
Rapamycin or Sirolimus is a potent anti-transplant rejection drug that can suppress and inhibit mTOR. mTOR
is a serine/threonine-protein kinase that is composed
of a two-part protein complex named mTORC1 and
mTORC2. mTORC1 is the complex that is sensitive
to rapamycin and other more common factors such as
oxygen, glucose, and various amino acids. mTORC2 is
insensitive to rapamycin and acts as an effector of insulin/IGF-1 (Insulin-like growth factor-1). The proteins s6,
p70S6K and 4E-BP1 are the point of control for many
cellular functions when phosphorylated by mTORC1.
This controls protein synthesis and the cell’s self-destruction mechanism known as autophagy. mTORC2 is mostly
required for other kinases such as Protein Kinase B. One
of the reasons that the mTOR pathway is so vital is that it
regulates pivotal moments in the life cycle of a cell including metabolism, transcription, proliferation, and eventually,
cell death. This has led mTOR, and by extension, rapamycin to be often studied in the examination of aging, also
known as cellular senescence (Husain et al, 2020).
Rapamycin first rose to prominence when it was discovered to block the immune system generally, and T cell
proliferation specifically. Additionally, mTOR is involved in
the cellular division cycle, playing a role in the transition
of the G1 to the S phase. Rapamycin as an inhibitor blocks
the cell cycle.This would suggest that mTOR can serve as
an important chokepoint in mitigating the spread of the
virus as it could block the proliferation of infected cells
(Husain et al, 2020).
In numerous studies examining the mortality of patients
with COVID-19, it was found that that a primary factor in
the occurrence of infectious diseases was blood Vitamin
D concentration. In a study of elderly patients, Vitamin D
helped reduce the inflammatory response in the upper
respiratory epithelium and lowered the risk of developing
intense symptoms (Grant et al , 2020).Vitamin D has also
been shown to interact with the ACE2 enzyme, limiting
the virus’s entry into the cell, as this serves as the entry
point for the SARS-COV-2 virus. Evidence would suggest
that the mechanism of action for the positive effects
of Vitamin D is the suppression of the mTOR pathway
through multiple mechanisms. One of these mechanisms
involves a regulator known as “regulated in development
and DNA damage response 1 (REDD1), a suppressor of
mTOR activity”, which is stimulated by the 1,25(OH)2D
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form of Vitamin D (Husain et al, 2020).
In all, it would be reasonable to suggest that the numerous benefits of Vitamin D are achieved through the inhibition of mTOR and can therefore be stimulated directly by
an mTOR inhibitory agent such as rapamycin.
The anti-aging effects of Rapamycin can be of great use
as well, with the drug being shown to extend the life of
mice significantly (Harrison et al, 2009). But, importantly for the treatment of COVID-19, Rapamycin has been
shown to rejuvenate damaged tissues such as damaged
cardiac cells and increase the vitality of hematopoietic
stem cells (Guarda et al, 2004). It may be that as proteins
are continuously synthesized, they acquire damage and
various misfolding that inhibit their function and are the
prime indicators of age-related diseases. The domain that
is affected by rapamycin is mTORC1. Inhibiting mTORC1
reduces protein synthesis and causes the cell to induce
autophagy, thereby recycling the damaged components.
COVID-19 has been proven to affect the elderly population at an increased rate, with higher mortality being
attributed, making rapamycin a potential anti-aging drug
that can mitigate the negative effects of age-related vulnerabilities (López-Otín et al, 2013). Additionally, it might
go some way in aiding with the reversal of organ damage
that is a hallmark of critical cases of COVID-19.
mTOR regulates metabolic processes that help to serve
as signaling for anabolic (building) and catabolic (dismantling)
processes in the cell. mTOR inhibition has been shown to
protect against high fat-induced obesity in mice by regulating
the breakdown of glycogen and other processes involving
glucose. This could make rapamycin useful in mitigating the
negative effects associated with insulin resistance and obesity in COVID-19 patients, which has been proven to result in
negative health outcomes (Saxton et. al. 2017).
Acute respiratory distress syndrome (ARDS) is caused
by the breakdown of upper respiratory epithelia that
results from a cytokine storm that destroys the body’s
tissues. This can lead to multi-organ failure that can often
be fatal. The various cytokines that are released are “IL-2,
IL-7, IL-10, MCP-1 (monocyte chemoattractant protein),
MIP1A (Macrophage Inflammatory Proteins) and TNF-α
(Tumor Necrosis Factor-α)”. Rapamycin’s primary effect
as an immunosuppressive drug can decrease the levels
of the cytokines in the body, making it a useful tool for
dealing with cytokine storms (Costela-Ruiz et al., 2020).
Rapamycin’s targeting and inhibition of a wide variety of
cytokines make it an ideal drug for the suppression of
harmful immune responses, making it potentially more
useful than the drug Tocilizumab and other monoclonal
antibodies that merely target individual cytokines.
Rapamycin’s inhibition of the mTOR pathway remains
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very promising not only for its pleiotropic effects on the
cell’s regulatory mechanisms but also for its anti-immune
properties. It is important to mention, however, that
rapamycin’s side effects can be rather unpredictable. This
makes it necessary to monitor the effects of rapamycin
in each patient and to educate them about the potential
negative side effects. There has been a proposal to examine upstream mutations in mTORC1 signaling to determine ideal candidates for therapeutic interventions using
rapamycin. This would help mitigate the negative side effects experienced by members of the patient population.
T-cell senescence is prevalent in long term infections
and cancer and is a state of T-cell dysfunction. Cytokine
storms can play a role in inducing T-cell apoptosis and necrosis, leading to overall lower T-cell counts. Patients with
COVID-19 have been observed to have lower CD4+,
CD8+, and total T-cell numbers which are all implicated in
lowering the survival rate of patients with the illness. Even
when the CD4+ and CD8+ cells are present in severely
ill COVID-19 patients, they exhibit less function overall
and are unable to secrete perforin, granzyme, and IFN-γ,
all of which are cytotoxic molecules. The senescent markers PD-1 and Tim-3 are also present at higher levels. Cells
that are senescent release certain cytokines and molecules
that are indicative of the cell’s status and are known as
the “senescence-associated secretory phenotype (SASP)”.
Rapamycin, being an mTOR inhibitor, can suppress SASP
and by extension the cytokine storm that results from
T-cell senescence. Therefore, administration of Rapamycin
in the early phase of the cytokine storm might prevent the
emergence of a severe form of COVID-19 through the
downregulation of SASP (Omarajee et al, 2020).
Rapamycin has a history of being beneficial regarding
respiratory infections, and has been shown to reduce the
recovery time in H1N1 and SARS patients. study that
examined 38 patients with H1N1-induced pneumonia,
reported that Rapamycin was associated with positive
outcomes in the overall prognosis of patients and shortened their time on a ventilator. It also was associated
with significantly increased viral clearance, lower rates of
hypoxemia, and reduced multiple organ dysfunction. Both
H1N1 and SARS-CoV-2 activate mTOR, leading to lung
inflammation, fever, and other intense immune reactions.
Rapamycin may provide a significant benefit by inactivating mTOR and therefore IL-1β secretion, the mediator of
inflammation (Wang et al., 2014).
Rapamycin is currently undergoing phase two clinical
trials to determine its efficacy in a 30-patient sample
that seeks to improve clinical outcomes in COVID-19
patients (NCT04341675). The study will last for 14 days
with 2mg being given orally daily. The primary outcome is

to determine the proportion of patients that do not need
advanced respiratory support by 28 days. The secondary
outcomes involve tracking changes in lymphocyte concentrations as biomarkers as well as the proportion of
patients requiring general respiratory support.
There have already been numerous studies done on
the use of rapamycin and metformin in the treatment of
a plethora of cancers and tumors, including pancreatic and
breast cancers (Faria et al, 2019; Amin et al, 2019). These
studies have determined the combination to be safe and
effective, with the combination able to target slightly different pathways than any of the two drugs alone. Rapamycin
can cause glucose intolerance and insulin resistance if
taken long term. These effects may be mitigated by metformin, due to metformin causing increased insulin sensitivity in tissues. The ITP (Intervention Testing Program)
reported that the effect of both rapamycin and metformin
on longevity when taken together was far superior to the
effect of each drug alone. It should be noted that in mice
the combination of the two drugs did reduce the effective
concentration of rapamycin in females and metformin in
both sexes. The final concentrations were still within the
range to be clinically useful (Strong et al, 2016).
In a study conducted on mice, examining the effects
of metformin on glucose, the animals were given both
rapamycin and metformin. Interestingly, in contrast to
studies that had been conducted previously, the researchers found that metformin did not inhibit mTOR and
stopped rapamycin from inhibiting mTOR in the liver. The
researchers theorized that metformin could alleviate the
disfunction in gluconeogenesis that was found in other
mTOR mutant mice (Kim et al, 2020).
Metformin and rapamycin would seem uniquely suited
for COVID-19 patients with obesity and diabetes. These
patients can be aided by glucose mitigation of metformin
but can also cycle lower doses of rapamycin for the potent
mTOR effects. In a study of rats being given rapamycin, the
researchers attempted to see if they could mitigate the
increased hepatic gluconeogenesis caused by rapamycin
administration by combining it with metformin.The female
mice in the study exhibited significantly lower gluconeogenesis, thereby implying that the metformin served to
remove the harmful side effects of rapamycin (Weiss et al,
2018). Here, as in our previous discussion, the effect was
sex-specific for many of the reasons outlined previously.
In a study examining metformin and rapamycin on the
proliferation of pancreatic cancer cell growth, the optimal
therapeutic dosage was determined to be (20 mmol/l)
Metformin + Rapamycin (200 ng/ml) in vivo. The study discovered that the combination was vastly more effective
than monotherapy at inhibiting mTOR (Zhang et al, 2018).
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Conclusion
In all, given the evidence that metformin reduces the
mortality and morbidity in diabetic patients, it should
remain a drug of primary importance in the treatment
of COVID-19 in diabetic patients. The effects of the drug
on insulin resistance can play an important part in reducing the immunosuppression found in diabetic patients
due to the abundance of glucose in the bloodstream. It
should be noted that the guidelines urging concern about
metformin inducing acidosis in patients was specifically applicable to patients already in multi-organ failure.
Additionally, even though the prevalence of acidosis was
higher in patients that were given metformin, it did not
affect the mortality rate(Cheng et al, 2020). As such, the
positive effects of metformin would make it an excellent
candidate for further study, not only in patients with preexisting comorbidities but as a possible therapeutic given
its anti-inflammatory properties. Metformin’s significant
effects on the RAAS system can make it an important
agent in the reduction of inflammatory cytokines that are
the hallmarks of COVID-19.
Regarding metformin in the treatment of patients with
COVID-19 and diabetes, it should be noted that many of
the studies are retrospective and examine patient outcomes using statistical analyses. They seek to determine
the efficacy of metformin in mitigating the detrimental
effects of diabetes on COVID-19 patients. The positive
effects of metformin previously noted, there is a paucity
of data of metformin being given to COVID-19 patients
without diabetes. Many of the studies specifically look
at the outcomes of patients who were previously given
metformin to control diabetes before the virus and were
then examined to determine the beneficial effects specifically on patients with diabetes and COVID-19. But for
such a widely prescribed drug such as metformin, it is
shocking that there exists so few clinical trials for individuals without diabetes as a comorbidity. Many papers
propose that metformin’s anti-inflammatory effects could
be of use to the wider population to reduce the negative
immune response, but as of the date of this paper, there
have not been any clinical trials examining the exact outcomes of the drug on a non-diabetic patient population.
There may be several reasons for the lack of clinical trials, among them, that even if metformin does show some
benefit in its ability to prevent an overzealous immune
response, other drugs currently being used or examined
in the treatment of COVID-19 are even more effective
through a similar mechanism. Tocilizumab, for example,
has already been shown to help in CAR T-cell-induced
cytokine release syndrome, which bears many similarities to the cytokine storm that can occur in COVID-19.
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A common side effect of Tocilizumab, however, is an elevation in blood pressure, which has proven damaging
in COVID-19 patients (Jones et al, 2010). Therefore, it
would be efficacious to conduct a thorough study of metformin, given its ability to be tolerated by a wide subset of
the population and its proposed benefits in its ability to
downregulate the immune system.
Additionally, many of the monoclonal antibody therapies that are being examined specifically exert their
effects on one target, while metformin has been shown
to operate across many different pathways. Metformin
lowers inflammation and oxidative stress, all the while
enhancing the immune system of patients.
Rapamycin can be a dangerous compound that must be
handled with caution due to its ability to act as a potent
inhibitor of mTOR. While mTOR inhibition can be beneficial in the reduction of inflammation, it is important
not to inhibit the pathway completely. A study examining
the effects of rapamycin on elderly patients discovered
that total inhibition of mTOR stops the function of T cells
and leads to complete immunosuppression. While some
suppression of the immune system is favorable due to
its effect on cytokine storms, the body’s natural defenses must remain viable. As such, the dose of rapamycin
must be carefully monitored to be safe and effective. In
that same study, they determined that the most effective
dose at promoting a healthy immune response in elderly
patients was the lowest dose of rapamycin followed by
a flu shot (Mannik et al., 2014). This has a great deal of
significance as of early 2021, due to the availability of the
mRNA COVID-19 vaccine currently seeing widespread
use. The use of rapamycin followed by a vaccine should
possibly be explored as a method of enhancing immunity
in vulnerable patient populations. This could maximize
the effectiveness of a protocol involving not only the currently available vaccine, but also carries implications for
other protocols involving vaccinations.
The combination of rapamycin and metformin used in
pancreatic cancer has been proven to be safe and effective. The dose used was the optimal dose to lower the
expression of mTOR in pancreatic cells, and it stands to
reason that this dosage would work in other cases where
mTOR should be partially inhibited, such as in COVID-19.
Rapamycin inhibits mTOR directly, while metformin does
it through the AMPK pathway (Zheng et al, 2020).
The dose of rapamycin administered must be carefully
controlled to avoid negative side effects. Metformin can
temper some of these effects, which can include insulin resistance and glucose intolerance, through its ability
to promote insulin sensitivity. Rather than administering
the two drugs as a cocktail, risk can be assessed by the
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administration of each drug separately. This would allow
a thorough examination of the differing effects while still
allowing metformin to counter the deleterious side effects of rapamycin.
An important point in discussions concerning the
treatment of viruses is the health of the host. It has been
demonstrated that immunocompromised patients and
those with significant comorbidities fare far worse than
patients without these complications. Metformin has the
dual role of not only directly combatting the virus, but
also reinforcing the immune system of the host. The ability to reduce comorbidities (e.g.: diabetes) should not be
treated flippantly. A major factor in the morbidity rate
in the United States has been a large proportion of the
population with high blood pressure and obesity (Azar
et al, 2020). These conditions have been proven to have
significant negative effects. If metformin can provide a
mechanism to reduce these additional comorbidities, the
patient’s health outcomes could be vastly improved.
Taking metformin to prevent an extremely negative
reaction to COVID-19 should be considered. Being that
metformin is a mild mitochondrial toxin that blocks
mTOR, it would be a useful preventative drug. mTOR
inhibitors have been shown to block viral action and express innate antiviral gene expression. In previous studies,
mTOR inhibitors were effective against other coronaviruses. Prescribing metformin to vulnerable patient populations as a preventative drug may grant the benefits of
mTOR inhibition without rapamycin’s toxic side effects
(Benedetti et al, 2020).
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